Summary

• T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer.
• MT027, the product of target B7H3 received US FDA orphan drug designation (ODD) on 2023 and will engage IND of US FDA in Q1...